Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04977453 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Start date: July 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent or in combination with pembrolizumab, lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid tumors.

NCT ID: NCT04977128 Recruiting - Solid Tumor, Adult Clinical Trials

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled KN035 (89Zr-KN035) PET Imaging in patients with PD-L1 positive solid tumors.

NCT ID: NCT04976634 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Start date: August 23, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and biliary tract cancer (BTC). There is no formal hypothesis testing in this study.

NCT ID: NCT04975958 Not yet recruiting - Clinical trials for Locally Advanced Solid Tumor

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Start date: July 30, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally advanced/metastatic tumors.

NCT ID: NCT04975308 Not yet recruiting - Breast Neoplasms Clinical Trials

Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

EMBER-3
Start date: August 13, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to measure how well LY3484356 works compared to hormone therapy in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.

NCT ID: NCT04975256 Recruiting - Metastatic Cancer Clinical Trials

Phase 1/1B Study in Patients With Cancer KRYSTAL 14

Start date: July 30, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.

NCT ID: NCT04975204 Not yet recruiting - Clinical trials for Advanced Malignant Tumor

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

Start date: August 2021
Phase: Phase 1
Study type: Interventional

TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.

NCT ID: NCT04973293 Not yet recruiting - Clinical trials for Lung Neoplasm Malignant

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved. Drugs targeting PD-1/PD-L1 pathway have been proven to be effective for late-stage NSCLC, and anti-angiogenesis agents targeting VEGF (bevacizumab) has also been used for the first line treatment of advanced or metastatic NSCLC. Therefore, we conduct this single-arm clinical trial, which aims to investigate the safety and feasibility of neoadjuvant sintilimab combined with bevacizumab and chemotherapy followed by surgery in treating locally advanced and resectable NSCLC.

NCT ID: NCT04972981 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Start date: August 20, 2021
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the safety and tolerability of ADCT-901.

NCT ID: NCT04972422 Not yet recruiting - Solid Tumors Clinical Trials

A Phase 1b Study of ZN-c3 as a Single Agent in Patients With Solid Tumors

Start date: July 30, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN c3.